As compared to non-users, there existed positive associations of increased HCC occurrences among current users of premixed insulin analogues (adjusted OR, 1.45; 95% CI 1.12 to 1.89), those with high cumulative dosages of premixed insulin analogues (adjusted OR, 1.62; 95% CI 1.16 to 2.26), and those with long (adjusted OR, 1.80; 95% CI 1.30 to 2.51) or short duration (adjusted OR, 1.41; 95% CI 1.03 to 1.93) of premixed insulin analogues. This evidence concerns the gene INS and hepatocellular carcinoma.